Universal Ibogaine Inc. holds a significant position over the TSX-V market with its greater difference between the lower and higher ranges of trading, which is $0.0400-$0.2500 in the last 52 weeks.
Gold is currently trading in range , we already seen good bounce from the recent Low/Support 1785, We have to wait how Price Behave if it test the marked Zone (High Volume Zone ) 1805 area .If able to hold on this zone then we can think about the buy otherwise more decline/Re-Test possible. **Previous Idea Comes true***
Hello Traders, Hope you all are doing good!! I expect US30 to go DOWN after finishing this correction. Look for your SELL setups. *This BUY is risky and I am biased only for short term upside, if you dont know how to manage your trade, dont take the risk now and wait for it to break the last low for HPB . Please follow me and like if you agree or this idea...
When Price consolidate near 200 Day Moving Average and break the upper boundary of the consolidation zone then high probability price continue the trend .
Metro brands has given a decent price breakout from the upper resistance and making higher highs. #stocks #trading
SOL has more to dump after breaking the significant support next levels to watch below are 26.1 - 24 - 20.75.
Universal Ibogaine Inc. is a Canadian Life science Company trading at OTC with ticker symbol $IBOGF currently sits at $0.0376 with volume around 10K+.
ADORWELD -- Looking at the chart pattern and trading data -- The monthly trend is +ve and the Weekly trend also Changed to +ve. The delivery percentage is increasing and currently avg is 62% Confluence: 20/50/100/150 - SMA -- all are currently within 2% of close. Crossed Monthly Pivot levels. Add to watch list -- possible BO.
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $139K+ in the last 3 months. The average volume of the company in the last 10 days is $81.88K with $190.74M share outstanding. The stock price when the market opened was $0.045.
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
After Months of consolidation -- WESTLIFE is about to crossover the trend line. Add to watch list and track it. Daily Trend changed to +ve and also Weekly Trend changed to +ve Currently Crossed 4-week High Close crossed Weekly 13 level and Delivery Percentage is above 50% on 20 days average. For the past 3 days Delivery % is above 75%.
WHEELS -- crossed trend line with decent above average volumes Volume is Monthly High The daily trend changed to positive High on momentum Above 20-SMA on Daily, Weekly, Monthly Time Frame Also, the Monthly trend is +ve & now the Weekly trend Changed to +ve. Please do your own research before making any investment
The business is happy to announce that PreCerv Inc. ("PreCerv") has been incorporated as a completely owned subsidiary. A worldwide field of use licence for NCP-01 and its autologous stem cell technology will be acquired by PreCerv from Hemostemix.
$IBO is gliding swiftly on the TSX-V Index, the shares are trading currently at $0.05 which might get doubled in the upcoming days or week maximum.
Dr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
"The significance of this occasion cannot be emphasized," said CEO Nick Karos. This is the first gathering of academic researchers, real-world technicians, and government policymakers of its sort. This event will raise awareness of ibogaine's great potential at the highest levels."
Hemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common shares of Hemostemix to directors, officers, employees and consultants of Hemostemix
Julie Dumouchel has been named Director of Clinical Trials at UI, which is a significant strategic move. Julie Dumouchel has 25 years of experience in the pharmaceutical sector, where she has worked in a variety of clinical research jobs and has a thorough grasp of the drug development process.